Tigo Expands TS4-A Platform with New Add-on UL-system-certified Rapid Shutdown Solution
18.3.2020 16:00:00 EET | Business Wire | Press release
Tigo Energy, Inc.®, pioneer of the smart modular Flex MLPE, today announced a new addition to the add-on TS4 Platform - the TS4-A-S. This add-on safety solution brings the solar market’s only module-level power electronic (MLPE) multivendor UL-system-certified solution for rapid shutdown. Tigo’s safety solution complies with NEC 2014, 2017, and 2020 with more than 100 inverters for residential, commercial & industrial, and utility customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200318005094/en/
The TS4-A-S provides module-level shutdown when installed on each PV module and accompanied by Tigo's communication accessories. Production data can be analyzed via Tigo’s SMART Website or App when connected to the cloud. Now taking orders for the TS4-A-S worldwide. (Photo: Business Wire)
The TS4-A-S provides module-level shutdown when installed on each PV module and accompanied by the Tigo Access Point (TAP) and the Cloud Connect Advanced (CCA). DC production data can be analyzed via Tigo’s SMART Website or App when connected to the cloud. This TS4-A-S launch accompanies the recently announced TS4-A-M (Monitoring Add-on) launch earlier this month. These units complete Tigo’s transition from the legacy TS4-R retrofit platform to the TS4-A add-on platform with mechanical upgrades, UHD-Core technology, expanded specifications to support PV modules up to 500W. To learn more, join Tigo's free online "Rapid Shutdown featuring the TS4-A-S & NEC 2020" webinar on Thursday, March 26th at 10am PT.
The highlights of the new TS4-A-S (Safety Add-on) with rapid shutdown include:
- Comply with NEC 2014, 2017, 2020 rapid shutdown requirements
- Choose compatibility from more than 100 UL-system-certified inverters
- Choose compatibility from any module up to 500W
- Manual or automatic shutdown in event of AC grid loss
- Automatic email or SMS alerts about faults or operational issues
- Protect PV system assets with full visibility of performance
- Lower O&M costs when identifying specific module problems
- Utilize module manufacturer warranties when tracking module failures
“Only inverters and rapid shutdown devices that have been UL-certified as a system are certified as safe. There’s one multivendor solution for residential C&I – and that’s Tigo,” says Danny Eizips, VP of Hardware Engineering at Tigo. “Others might not meet mandatory safety requirements, and therefore, cannot be trusted as safe when installed together in one PV system. We're working diligently to educate our partners and customers worldwide to know the difference for the safest solar experience.”
Tigo is now taking orders for the TS4-A-S worldwide. The last inventory of legacy TS4-R-S units may be shipped per the discretion of Tigo and Tigo’s distribution partners as the new TS4-A-S shipments are prepared. Both units are fully backward compatible. For price and delivery, consult your preferred solar distributor, call Tigo at +1.408.402.0802, email sales@tigoenergy.com, or visit www.tigoenergy.com.
About Tigo Energy, Inc.
Tigo is a Silicon Valley company founded in 2007 by a team of experienced technologists. Combining a unique systems-level approach with expertise in semiconductors, power electronics, and solar energy, the Tigo team developed the first-generation Smart Module Optimizer technology for the solar industry. Tigo's vision is to leverage integrated and retrofitted Flex MLPE and communications technology to drive the cost of solar electricity down. By partnering with tier 1 module and inverter manufacturers in the industry, Tigo is able to focus on its key innovation with the smartest TS4 modular platform and leverage the broader ecosystem. Tigo has operations in the USA, Europe, Latin America, Japan, China, Australia, and the Middle East. Visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005094/en/
Contact information
Tiffany Douglass
408.402.0802 x 430
marketing@tigoenergy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 14:20:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 14:15:00 EEST | Press release
Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined by much of the institutional investment community. Xsolla's presence at SuperReturn International reflects a broader moment: the convergence of a mu
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release
Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom